The American College of Toxicology is proud to offer a new eLearning Seminar focused on development of CNS/Neurology Therapeutics. These four modules are intended to provide insight into the development of therapeutics for CNS/Neurology diseases, focusing on the regulatory and nonclinical considerations for safety assessment of therapies encompassing standard and novel modalities, including small molecules, biologics, anti-sense oligonucleotides (ASOs)/miRNA, and advanced cell and gene therapies.
Module 1: Regulatory Considerations for the Development of CNS/Neurology Therapeutics
Module 2: Nonclinical Development of AAV-Based Gene Therapy for Spinal Muscular Atrophy
Module 3: Nonclinical Development of Antisense Oligonucleotide for Spinal Muscular Atrophy
Module 4:
Part 1: Development of Biologics for CNS Diseases
Part 2: The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations
For more information and registration, please visit: ACT eLearning